Cargando…

Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues

Background: Novel Psychoactive Substances (NPS) are a heterogeneous class of synthetic molecules including synthetic cannabinoid receptor agonists (SCRAs). Psychosis is associated with SCRAs use. There is limited knowledge regarding the structured assessment and psychometric evaluation of clinical p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonaccorso, Stefania, Metastasio, Antonio, Ricciardi, Angelo, Stewart, Neil, Jamal, Leila, Rujully, Naasir-Ud-Dinn, Theleritis, Christos, Ferracuti, Stefano, Ducci, Giuseppe, Schifano, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071094/ https://www.ncbi.nlm.nih.gov/pubmed/30011896 http://dx.doi.org/10.3390/brainsci8070133

Ejemplares similares

Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report
por: Bonaccorso, Stefania, et al.
Publicado: (2021)

Increased violence and aggression levels during the SARS-Cov-2 pandemic; data from three London acute psychiatric inpatient facilities.
por: Bonaccorso, S., et al.
Publicado: (2023)

Neutropenia in patients under treatment with clozapine and COVID-19 infection
por: Bonaccorso, S., et al.
Publicado: (2021)

2273 Synthetic cannabinoid usage among psychiatric inpatients
por: Mann, Claire L., et al.
Publicado: (2018)

The e-Psychonauts’ ‘Spiced’ World; Assessment of the Synthetic  Cannabinoids’ Information Available Online
por: Zangani, Caroline, et al.
Publicado: (2020)

Emerging synthetic cannabinoids and the risk of psychosis: a growing concern for public health
por: Souza, José Diogo R., et al.
Publicado: (2023)

Rabies infection recognized as a psychosis: A misleading psychiatric presentation
por: Ferdaouss, Qassimi, et al.
Publicado: (2023)

Perfusion Index Analysis in Patients Presenting to the Emergency Department Due to Synthetic Cannabinoid Use
por: Yeniocak, Selman
Publicado: (2019)

Synthetic cannabinoids
por: Bilici, Rabia
Publicado: (2014)

Cannabinoids, reward processing, and psychosis
por: Gunasekera, Brandon, et al.
Publicado: (2021)

Medicinal Cannabis and Synthetic Cannabinoid Use
por: Pichini, Simona, et al.
Publicado: (2020)

Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice
por: Clerici, Massimo, et al.
Publicado: (2018)

An Adolescent Female With Concurrent Presentation of Autoimmune Hepatitis and Secondary Syphilis
por: Riddell, Madison, et al.
Publicado: (2023)

Neurosyphilis-Induced Psychosis: A Unique Presentation of Syphilis With a Primary Psychiatric Manifestation
por: Taki El-Din, Zaid, et al.
Publicado: (2023)

MYXOEDEMA PRESENTING WITH PSYCHOSIS
por: Rao, Ashok Chandra R, et al.
Publicado: (1990)

Severe Vitamin K-dependent Coagulopathy from Rodenticide-contaminated Synthetic Cannabinoids: Emergency Department Presentations
por: Wright, Erik, et al.
Publicado: (2021)

First-Episode of Synthetic Cannabinoid-Induced Psychosis in a Young Adult, Successfully Managed with Hospitalization and Risperidone
por: Roberto, Aaron J., et al.
Publicado: (2016)

Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis
por: Theunissen, Eef L., et al.
Publicado: (2021)

Anti-Neuronal Autoantibodies (Cell Surface and Onconeural) and Their Association With Natural Autoantibodies in Synthetic Cannabinoid-Induced Psychosis
por: Hau, Lídia, et al.
Publicado: (2022)

Cannabinoid hyperemesis syndrome presenting with ventricular bigeminy
por: Wong, Jeffrey, et al.
Publicado: (2023)

Autoimmune Thyroiditis Presenting as Psychosis
por: DAS, Soumitra, et al.
Publicado: (2017)

Thyroid Storm Presenting as Psychosis
por: Desai, Dimpi, et al.
Publicado: (2018)

Neurobrucellosis Presenting as Acute Psychosis
por: Shah, Irfan Ahmad, et al.
Publicado: (2018)

Effectiveness of the synthetic cannabinoids seminar
por: Seyit, Murat, et al.
Publicado: (2016)

Synthetic cannabinoids and renal injury
por: Alp, Alper
Publicado: (2015)

Fugue and aphonia as first and foremost presentations of a case of psychosis
por: Leotsakou, Christina, et al.
Publicado: (2010)

Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study
por: Hobbs, Melissa, et al.
Publicado: (2020)

Sheehan's syndrome presenting as psychosis: a rare clinical presentation
por: Shoib, Sheikh, et al.
Publicado: (2013)

Prospects for the Use of Cannabinoids in Psychiatric Disorders
por: Graczyk, Michał, et al.
Publicado: (2021)

Varied Presentations of Pediatric Patients With Positive Cannabinoid Tests
por: Harvey, Taylor, et al.
Publicado: (2022)

Baclofen Overdose Presenting as Psychosis with Catatonia
por: Nahar, Abhinav, et al.
Publicado: (2017)

Syphilis presenting as late-onset psychosis
por: Das, Suhasini, et al.
Publicado: (2022)

Psychosis as acute presentation in Hashimoto's thyroiditis
por: Gondwal, Rohit, et al.
Publicado: (2021)

Acute psychosis as the presenting manifestation of lupus
por: Kumar, Piyush, et al.
Publicado: (2021)

A case of Astrocytoma presented with Psychosis
por: Patel, Beejal M., et al.
Publicado: (2022)

Characterization of the synthetic cannabinoid MDMB-CHMCZCA
por: Weber, Carina, et al.
Publicado: (2016)

Broadly Neutralizing Synthetic Cannabinoid Vaccines
por: Lin, Mingliang, et al.
Publicado: (2020)

Synthetic Cannabinoids: An Emerging Cause of Coagulopathy
por: Ullah, Shakir, et al.
Publicado: (2020)

Methadone Gastrobezoar in a Psychiatric Patient Presented in Coma
por: Gavala, Alexandra, et al.
Publicado: (2017)

Neuroacanthocytosis Presenting with Psychiatric Symptoms
por: Srivatsa,, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_iouql3halg04e7v9ebevpmfvvl